WO2026125390 - FTHL17 IMMUNOGEN AND TCR
National phase entry is expected:
Publication Number
WO/2026/125390
Publication Date
18.06.2026
International Application No.
PCT/EP2025/086152
International Filing Date
09.12.2025
Title **
[English]
FTHL17 IMMUNOGEN AND TCR
[French]
IMMUNOGÈNE DE FTHL17 ET TCR
Applicants **
VIB VZW
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
LAMBRECHTS, Diether
BRICARD, Orian
Priority Data
24218255.8
09.12.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2363 | |
| EPO | Filing, Examination, Granting | 11046 | |
| Japan | Filing, Examination, Granting | 2285 | |
| South Korea | Filing, Examination, Granting | 2304 | |
| USA | Filing, Examination, Granting | 10740 |
Total:
28,738
Contact Us
Abstract[English]
The invenon relates to immunogenic pepdes, HLA-immunogenic pepde complexes, and T cell receptors (TCRs) recognizing such HLA-immunogenic pepde complexes. These interacng partners were in parcular obtained starng from TCRs of T cell clones expanding in a cancer paent upon immune checkpoint inhibitor treatment. In parcular, the immunogenic pepdes are derived from the FTHL17 protein. The idenficaon of these clinically relevant molecular interacons provides mulple therapeuc opons and diagnosc tools, including methods for selecng subjects eligible for such therapies.[French]
L'invention concerne des peptides immunogènes, des complexes HLA-peptide immunogène et des récepteurs de lymphocytes T (TCR) reconnaissant de tels complexes HLA-peptide immunogène. Ces partenaires d'interaction ont notamment été obtenus à partir de TCR de clones de lymphocytes T se développant chez un patient atteint de cancer sous traitement par inhibiteur de point de contrôle immunitaire. Plus particulièrement, les peptides immunogènes sont dérivés de la protéine FTHL17. L'identification de ces interactions moléculaires cliniquement pertinentes offre de multiples options thérapeutiques et outils diagnostiques, y compris des méthodes pour sélectionner des sujets éligibles pour de telles thérapies.